Related Experiment Videos
Prognostic assessment of various parameters in chronic myeloid leukemia
Insights
For chronic myeloid leukemia (CML) patients, achieving first remission quickly significantly improves survival. Smaller spleen size and longer remission duration also positively impact prognosis, unlike other common clinical factors.
Area of Science:
- Hematology
- Oncology
- Medical Statistics
Background:
- Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm.
- Prognostic factors are crucial for managing CML and predicting patient outcomes.
Purpose of the Study:
- To identify statistically significant prognostic factors for survival in chronic myeloid leukemia (CML) patients.
- To evaluate the prognostic value of various clinical and laboratory parameters in CML.
Main Methods:
- Retrospective analysis of 152 chronic myeloid leukemia (CML) cases.
- Statistical evaluation of individual parameters against patient survival data.
- Comparison of median survival (MS) based on prognostic indicators.
Main Results:
- Age, sex, symptom duration, hepatomegaly, hemoglobin, leukocyte, and platelet counts were not significant prognostic factors.
- Splenomegaly < 10 cm and first remission duration ≥ 6 months correlated with significantly longer MS.
- Time to achieve first remission was the most significant prognostic factor: MS was 70 months (≤ 2 months) vs. 23.5 months (> 2 months).
Conclusions:
- Early achievement of first remission is a critical prognostic indicator in CML.
- Spleen size and duration of first remission also hold prognostic value.
- Several commonly assessed parameters lack prognostic significance in CML survival.
Abstract:
In 152 cases of chronic myeloid leukemia (CML) (actuarial median survival [MS], 59.2 months), the statistical relation of individual parameters with survival was studied to ascertain their prognostic value. The following parameters were found to be unrelated to the survival: age, sex, duration of symptoms, sternal bone tenderness, degree of hepatomegaly, level of hemoglobin, and leukocyte and platelet counts at the time of diagnosis. Splenomegaly of less than 10 cm and duration of first remission of 6 months or more were associated with significantly longer survival (MS, 70.5 and 68.5 months, respectively) as compared to bigger spleen size and duration of remission of less than 6 months (MS, 50.5 and 26 months; P less than 0.01 and P less than 0.05, respectively). The most significant prognostic parameter was the time required to achieve first remission. MS was 70 months in patients who achieved first remission in 2 months or less; it was 23.5 months in the remaining patients. This difference was statistically highly significant (P less than 0.001).